GHANA has become the first country to approve an effective malaria vaccine developed at Oxford University in the UK.
The R21/Matrix-M vaccine, the first to exceed the World Health Organization's target of 75% efficacy, has been cleared for use by Ghana's Food and Drugs Authority for children aged five to 36 months, the group at highest risk of death from malaria, The Guardian has reported.
Prof Adrian Hill, Director, Jenner Institute, which is part of the Nuffield Department of Medicine at Oxford University, said, "this marks a culmination of 30 years of malaria vaccine research at Oxford".
However, observers warned it was "no silver bullet" in the complex fight against the mosquito-borne disease.
In Ghana, an estimated 5.3m cases and 12,500 deaths were recorded.
The above article was sent to subscribers in Pharmacy Daily's issue from 19 Apr 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 Apr 23
Warning: Undefined variable $o_shortcode_atts in /home/pharmacydaily.com.au/public_html/wp-content/themes/child-custom-theme/functions.php on line 1263
Warning: Undefined variable $output in /home/pharmacydaily.com.au/public_html/wp-content/themes/child-custom-theme/functions.php on line 1266
